This Article 
   
 Share 
   
 Bibliographic References 
   
 Add to: 
 
Digg
Furl
Spurl
Blink
Simpy
Google
Del.icio.us
Y!MyWeb
 
 Search 
   
Creativity is Key to Drug R&D
May/June 1999 (vol. 1 no. 3)
pp. 6-9
ASCII Text
x 
 
Keri Schreiner, "Creativity is Key to Drug R&D," Computing in Science and Engineering, vol. 1, no. 3, pp. 6-9, May/June, 1999.
 
 
BibTex
x
 
@article{ 10.1109/5992.764208,
author = {Keri Schreiner},
title = {Creativity is Key to Drug R&D},
journal ={Computing in Science and Engineering},
volume = {1},
number = {3},
issn = {1521-9615},
year = {1999},
pages = {6-9},
doi = {http://doi.ieeecomputersociety.org/10.1109/5992.764208},
publisher = {IEEE Computer Society},
address = {Los Alamitos, CA, USA},
}
 
 
RefWorks Procite/RefMan/Endnote
x 
 
TY - MGZN
JO - Computing in Science and Engineering
TI - Creativity is Key to Drug R&D
IS - 3
SN - 1521-9615
SP6
EP9
EPD - 6-9
A1 - Keri Schreiner,
PY - 1999
VL - 1
JA - Computing in Science and Engineering
ER -
 
In a world where time to market is money, the pharmaceutical industry faces special challenges. According to Eli Lilly and Company, only one in every 10,000 chemical compounds studied will complete the gauntlet of chemical analysis, testing, clinical trials, and regulatory-agency approval to actually make it to market. On average, the cost for each survivor is $500 million and 15 years of development time.
Citation:
Keri Schreiner, "Creativity is Key to Drug R&D," Computing in Science and Engineering, vol. 1, no. 3, pp. 6-9, May-June 1999, doi:10.1109/5992.764208
Usage of this product signifies your acceptance of the Terms of Use.